{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:18:45Z","timestamp":1788221925162,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004767","name":"University of Science and Technology Liaoning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101363","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:27:58Z","timestamp":1769844478000},"page":"101363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL"],"prefix":"10.1016","volume":"76","author":[{"given":"Xiaoxiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.blre.2026.101363_bb0005","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101363_bb0010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.blre.2026.101363_bb0015","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2026.101363_bb0020","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2026.101363_bb0025","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2026.101363_bb0030","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0035","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.blre.2026.101363_bb0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2026.101363_bb0050","article-title":"Antibody-drug conjugates: The last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"18","key":"10.1016\/j.blre.2026.101363_bb0055","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","article-title":"Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives","volume":"102","author":"Prince","year":"2023","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0065","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0070","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/14712598.2020.1777979","article-title":"Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Malecek","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"24","key":"10.1016\/j.blre.2026.101363_bb0075","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1158\/1078-0432.CCR-24-1729","article-title":"FDA approval summary: Polatuzumab Vedotin in the first-line treatment of select large B-cell lymphomas","volume":"30","author":"Sarraf Yazdy","year":"2024","journal-title":"Clin Cancer Res Offl J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101363_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14712598.2025.2453524","article-title":"The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma","volume":"25","author":"Ahmed","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"15","key":"10.1016\/j.blre.2026.101363_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17152479","article-title":"Bispecific antibodies and antibody-drug conjugates in relapsed\/refractory aggressive non-Hodgkin lymphoma, focusing on diffuse large B-cell lymphoma","volume":"17","author":"Caserta","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Investig"},{"issue":"3","key":"10.1016\/j.blre.2026.101363_bb0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0952-7915(00)00215-6","article-title":"New views of BCR structure and organization","volume":"13","author":"Matsuuchi","year":"2001","journal-title":"Curr Opin Immunol"},{"issue":"13","key":"10.1016\/j.blre.2026.101363_bb0105","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab Vedotin: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0110","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101363_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101363_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101363_bb0125","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2022-165699","article-title":"Polatuzumab Vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"140","author":"Herrera","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101363_bb0130","series-title":"EHA2025 Congress","article-title":"Polatuzumab vedotin, rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) for relapsed\/refractory diffuse large B-cell lymphoma: results from the randomized phase III POLARGO trial","volume":"43","author":"Sancho","year":"2025"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"issue":"36","key":"10.1016\/j.blre.2026.101363_bb0145","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1200\/JCO-25-00992","article-title":"Efficacy and safety of Glofitamab plus Polatuzumab Vedotin in relapsed\/refractory large B-cell lymphoma including high-grade B-cell lymphoma: results from a phase Ib\/II trial","volume":"43","author":"Hutchings","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101363_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00345-9","article-title":"Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"11","author":"Abrisqueta","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101363_bb0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-136361","article-title":"Polatuzumab Vedotin plus Venetoclax with rituximab in relapsed\/refractory diffuse large B-cell lymphoma: primary efficacy analysis of a phase Ib\/II study","volume":"136","author":"Gritti","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0160","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ajh.27341","article-title":"Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"99","author":"Yuen","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101363_bb0165","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.1182\/blood-2024-203066","article-title":"Polatuzumab Vedotin-based regimens as bridging therapy before chimeric antigen receptor T-cell therapy for relapsed\/refractory diffuse large B cell lymphoma","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2026.101363_bb0170","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Blood Adv"},{"issue":"S3","key":"10.1016\/j.blre.2026.101363_bb0175","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971588.68510.b0","article-title":"P1173: Early administration of Polatuzumab Vedotin as bridging CD19-specific chimeric antigen receptor t cell therapy is an effective strategy to improve survival in patients with r\/r b-cell lymphoma","volume":"7","author":"Yang","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2026.101363_bb0180","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1182\/blood-2021-152313","article-title":"Polatuzumab Vedotin use before chimeric antigen receptor T-cell (CAR-T) therapy in aggressive lymphoma: a US single center experience","volume":"138","author":"Khurana","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0185","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0190","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101363_bb0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101363_bb0200","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2024-197938","article-title":"Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of Polatuzumab Vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes","volume":"144","author":"Salles","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2026.101363_bb0205","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/bloodadvances.2022009145","article-title":"Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas","volume":"7","author":"Lynch","year":"2023","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.blre.2026.101363_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7549","article-title":"Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study","volume":"41","author":"Dickinson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101363_bb0215","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-174081","article-title":"Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): A 12-month analysis from a phase Ib study","volume":"142","author":"Topp","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101363_bb0220","series-title":"280 | Glofitamab Combined with r-CHOP or POLA-r-CHP in Patients with Previously Untreated Diffuse Large b-cell Lymphoma: Final Results from the NP40126 Study","author":"Topp","year":"2025"},{"issue":"23","key":"10.1016\/j.blre.2026.101363_bb0225","first-page":"2595","article-title":"Glofitamab combined with Pola-R-CHP or R-CHOP as first therapy in younger patients with high-risk large B-Cell lymphoma","volume":"43","author":"Minson","year":"2025","journal-title":"Results from the COALITION study"},{"issue":"12","key":"10.1016\/j.blre.2026.101363_bb0230","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1038\/s41375-024-02420-6","article-title":"Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials","volume":"38","author":"Lenz","year":"2024","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101363_bb0235","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-188854","volume":"142","author":"Melchardt","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2026.101363_bb0240","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood.2023022048","article-title":"Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis","volume":"142","author":"Russler-Germain","year":"2023","journal-title":"Blood"},{"issue":"7277","key":"10.1016\/j.blre.2026.101363_bb0245","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0250","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"issue":"5\u20136","key":"10.1016\/j.blre.2026.101363_bb0255","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0260","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.blre.2026.101363_bb0265","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab Tesirine: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"19","key":"10.1016\/j.blre.2026.101363_bb0270","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101363_bb0275","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101363_bb0280","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173645","article-title":"Loncastuximab Tesirine demonstrated substantial single-agent efficacy and manageable safety profile in heavily pretreated Chinese patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2026.101363_bb0285","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3324\/haematol.2023.284197","article-title":"Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy","volume":"109","author":"Tarantelli","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101363_bb0290","article-title":"ABCL-515 updated results of the safety run-in of the phase 3 LOTIS-5 trial: novel combination of Loncastuximab Tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R\/R DLBCL","volume":"23","author":"Kwiatek","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101363_bb0300","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1016\/S2152-2650(25)02300-6","article-title":"ABCL-777: initial results from LOTIS-7: A phase 1b study of Loncastuximab Tesirine plus Glofitamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"25","author":"Alderuccio","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101363_bb0305","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2021-147765","article-title":"Planned interim analysis of a phase 2 study of Loncastuximab Tesirine plus Ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3)","volume":"138","author":"Carlo-Stella","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2026.101363_bb0310","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","article-title":"CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy","volume":"4","author":"Thapa","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2026.101363_bb0315","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood.2024025673","article-title":"Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T\/-NK cells and reduces trogocytosis","volume":"145","author":"Koh","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.11.005","article-title":"The AntiCD19 antibody drug Immunoconjugate Loncastuximab achieves responses in DLBCL relapsing after AntiCD19 CAR-T cell therapy","volume":"22","author":"Caimi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2, Supplement","key":"10.1016\/j.blre.2026.101363_bb0325","article-title":"Real-world clinical effectiveness of Loncastuximab Tesirine monotherapy for the treatment of relapsed\/refractory diffuse large B-cell lymphoma following chimeric antigen T cell therapy in the US","volume":"30","author":"Epperla","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0330","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41408-024-01195-4","article-title":"Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"14","author":"Epperla","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.blre.2026.101363_bb0335","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","article-title":"Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy","volume":"59","author":"Iqbal","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0340","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1021\/acs.molpharmaceut.5b00175","article-title":"Design of Coltuximab Ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies: structure-activity relationships and preclinical evaluation","volume":"12","author":"Hong","year":"2015","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.blre.2026.101363_bb0345","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","article-title":"A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy","volume":"103","author":"Trn\u0115n\u00fd","year":"2018","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.blre.2026.101363_bb0350","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.182.182","article-title":"A phase 1 study of Denintuzumab Mafodotin (SGN-CD19A) in relapsed\/refactory B-Lineage Non-Hodgkin lymphoma","volume":"126","author":"Moskowitz","year":"2015","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.blre.2026.101363_bb0355","doi-asserted-by":"crossref","first-page":"12450","DOI":"10.1021\/jacs.7b03208","article-title":"CD22 ligands on a natural N-glycan scaffold efficiently deliver toxins to B-lymphoma cells","volume":"139","author":"Peng","year":"2017","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0360","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.12862","article-title":"Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia","volume":"98","author":"Thota","year":"2017","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0365","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-12-1173","article-title":"DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma","volume":"12","author":"Li","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0370","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase I study of the anti-CD22 antibody-drug conjugate Pinatuzumab Vedotin with\/without rituximab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clin Cancer Res Offl J Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.blre.2026.101363_bb0375","first-page":"740","article-title":"Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic","volume":"375","author":"Kantarjian","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2026.101363_bb0380","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0385","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/21556660.2017.1315336","article-title":"Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed\/refractory CD22+ B-cell non-Hodgkin lymphoma","volume":"6","author":"Sangha","year":"2017","journal-title":"J Drug Assess"},{"issue":"19","key":"10.1016\/j.blre.2026.101363_bb0390","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-15-2488","article-title":"Phase I study of Inotuzumab Ozogamicin combined with R-CVP for relapsed\/refractory CD22+ B-cell non-Hodgkin lymphoma","volume":"22","author":"Ogura","year":"2016","journal-title":"Clin Cancer Res Offl J Am Assoc Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0395","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","article-title":"Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0400","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2026.101363_bb0405","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3109\/10428194.2015.1017821","article-title":"A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"56","author":"Wagner-Johnston","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101363_bb0410","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-142859","article-title":"A phase I pharmacokinetic (PK) and safety study of Trph-222 in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R NHL): dose-escalation results","volume":"136","author":"Hernandez-Ilizaliturri","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2026.101363_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.blre.2026.101363_bb0420","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2018-99-115986","article-title":"Adct-301 (Camidanlumab Tesirine), a novel Pyrrolobenzodiazepine-based CD25-targeting antibody drug conjugate, in a phase 1 study of relapsed\/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma","volume":"132","author":"Collins","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101363_bb0425","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","article-title":"Phase 1 study of Adct-301 (Camidanlumab Tesirine), a novel Pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma","volume":"132","author":"Hamadani","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2026.101363_bb0435","first-page":"1620","article-title":"CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications","volume":"9","author":"de Bruin","year":"1995","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.blre.2026.101363_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/cells12131783","article-title":"The polyvalent role of CD30 for cancer diagnosis and treatment","volume":"12","author":"Dumitru","year":"2023","journal-title":"Cells"},{"issue":"22","key":"10.1016\/j.blre.2026.101363_bb0445","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","article-title":"Brentuximab vedotin","volume":"124","author":"Ansell","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2026.101363_bb0450","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"de Claro","year":"2012","journal-title":"Clin Cancer Res Offl J Am Assoc Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2026.101363_bb0455","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2026.101363_bb0460","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.2021011894","article-title":"Phase 1\/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma","volume":"139","author":"Ward","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2026.101363_bb0465","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab Vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0470","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.blre.2026.101363_bb0475","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood-2016-11-748137","article-title":"Staining the target: CD37 expression in lymphomas","volume":"128","author":"Bertoni","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0480","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl Auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: A new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"10.1016\/j.blre.2026.101363_bb0485","first-page":"3976","article-title":"A phase 1 study of the anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies","volume":"126","author":"Sawas","year":"2015","journal-title":"Interim Results Blood"},{"key":"10.1016\/j.blre.2026.101363_bb0490","series-title":"A First in Human Experience of the Anti-CD37 Antibody-drug Conjugate AGS67E in Lymphoid Malignancies","author":"Sawas","year":"2016"},{"issue":"5","key":"10.1016\/j.blre.2026.101363_bb0495","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","article-title":"Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study","volume":"36","author":"Stathis","year":"2018","journal-title":"Investig New Drugs"},{"issue":"9","key":"10.1016\/j.blre.2026.101363_bb0500","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2017.06.001","article-title":"The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models","volume":"19","author":"Hicks","year":"2017","journal-title":"Neoplasia (New York, NY)"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101363_bb0505","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-145102","article-title":"Safety and efficacy of CD37-targeting naratuximab Emtansine PLUS Rituximab in diffuse large B-cell Lymphoma and other NON-Hodgkin\u2019S B-cell lymphomas - a phase 2 study","volume":"138","author":"Levy","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0510","first-page":"12","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0515","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Investig New Drugs"},{"issue":"2","key":"10.1016\/j.blre.2026.101363_bb0520","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Investig New Drugs"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0525","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2909-2","article-title":"First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70","volume":"77","author":"Owonikoko","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0530","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cjp2.114","article-title":"High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74-drug conjugate","volume":"5","author":"Zhao","year":"2019","journal-title":"J Pathol Clin Res"},{"issue":"102","key":"10.1016\/j.blre.2026.101363_bb0535","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101363_bb0540","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-139829","article-title":"Preliminary results of an ongoing phase 1 dose escalation study of the novel anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in patients with B-cell Non-Hodgkin Lymphoma","volume":"136","author":"Shah","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8060170","article-title":"ROR1 is expressed in diffuse Large B-Cell Lymphoma (DLBCL) and a small molecule inhibitor of ROR1 (KAN0441571C) induced apoptosis of lymphoma cells","volume":"8","author":"Ghaderi","year":"2020","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.blre.2026.101363_bb0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313026","article-title":"Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types","volume":"19","author":"Silva","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2026.101363_bb0555","series-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","author":"Wang","year":"2022"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101363_bb0560","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139468","article-title":"VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101363_bb0565","series-title":"Open-label, Active-control, Phase 2\/3 Study of Zilovertamab vedotin plus Standard of Care in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma","author":"Cobb","year":"2022"},{"issue":"22","key":"10.1016\/j.blre.2026.101363_bb0570","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","article-title":"Antibody-drug conjugates and small molecule-drug conjugates: Opportunities and challenges for the development of selective anticancer cytotoxic agents","volume":"58","author":"Casi","year":"2015","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.blre.2026.101363_bb0575","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0580","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.blre.2026.101363_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regulat Toxicol Pharmacol RTP"},{"issue":"12","key":"10.1016\/j.blre.2026.101363_bb0590","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2026.101363_bb0595","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0600","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2026.101363_bb0605","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2026.101363_bb0610","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention","volume":"14 Suppl 4","author":"Grisold","year":"2012","journal-title":"Neuro-oncology"},{"issue":"8","key":"10.1016\/j.blre.2026.101363_bb0615","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2026.101363_bb0620","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf228","article-title":"The adverse event of interstitial lung disease in patients treated with antibody-drug conjugates","author":"Fang","year":"2025","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.blre.2026.101363_bb0625","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101363_bb0630","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem Soc Rev"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101363_bb0635","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-137451","article-title":"A phase I study of the anti-CD79b THIOMABTM-drug conjugate DCDS0780A in patients (pts) with relapsed or refractory B-cell non-Hodgkin\u2019s Lymphoma (B-NHL)","volume":"130","author":"Herrera","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101363_bb0640","series-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy","first-page":"101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0645","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to Brentuximab Vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"10.1016\/j.blre.2026.101363_bb0650","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178662","article-title":"Sequencing anti-CD19 therapies in diffuse large B-cell lymphoma: from mechanistic insights to clinical strategies","volume":"26","author":"Laddaga","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.blre.2026.101363_bb0655","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2009-02-205500","article-title":"Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2026.101363_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101363_bb0665","article-title":"Antibody-drug conjugates in oncology: A spotlight on overcoming resistance","volume":"217","author":"Xu","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.blre.2026.101363_bb0670","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-20-0222","article-title":"The role of specific ATP-binding cassette transporters in the acquired resistance to Pyrrolobenzodiazepine dimer-containing antibody-drug conjugates","volume":"19","author":"Corbett","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.blre.2026.101363_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and challenges in antibody-drug conjugates for cancer therapy: a new era for cancer treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.blre.2026.101363_bb0680","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186882","article-title":"Design and validation of linkers for site-specific preparation of antibody-drug conjugates carrying multiple drug copies per cysteine conjugation site","volume":"21","author":"Kumar","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0685","article-title":"Site-specific antibody conjugation to engineered double cysteine residues","volume":"14","author":"Zhou","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"8","key":"10.1016\/j.blre.2026.101363_bb0690","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.blre.2026.101363_bb0695","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.blre.2026.101363_bb0700","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.blre.2026.101363_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.blre.2026.101363_bb0710","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2026.101363_bb0715","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1016\/j.blre.2026.101363_bb0720","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"24","key":"10.1016\/j.blre.2026.101363_bb0725","first-page":"2220","volume":"387","author":"Dickinson","year":"2022","journal-title":"Glofitamab Relapsed Refract Diffuse Large B-Cell Lymphoma"},{"issue":"10466","key":"10.1016\/j.blre.2026.101363_bb0730","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"15","key":"10.1016\/j.blre.2026.101363_bb0735","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:08:48Z","timestamp":1788221328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":146,"alternative-id":["S0268960X26000020"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101363","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101363"}}